Viatris Inc. logo

Viatris Inc. (US92556V1061)

Market Open
5 Dec, 13:07
9. 22
-0.02
-0.17%
- Market Cap
6.8 P/E Ratio
0.48% Div Yield
500 Volume
2.95 Eps
9.24
Previous Close
Day Range
9.22 9.22
Year Range
6.34 12.46
Want to track US92556V1061 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 83 days

Summary

US92556V1061 trading today lower at €9.22, a decrease of 0.17% from yesterday's close, completing a monthly increase of 1.56% or €0.14. Over the past 12 months, US92556V1061 stock lost -23.02%.
US92556V1061 pays dividends to its shareholders, with the most recent payment made on Sep 15, 2025. The next announced payment will be in In 1 weeks on Dec 15, 2025 for a total of €0.12.
The last earnings report, released on Nov 10, 2025, missed the consensus estimates by -0.62%. On average, the company has fell short of earnings expectations by -0.19%, based on the last three reports. The next scheduled earnings report is due on Feb 26, 2026.
Viatris Inc. has completed 10 stock splits, with the recent split occurring on Oct 09, 2003.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

US92556V1061 Chart

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seekingalpha | 2 days ago
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seekingalpha | 3 days ago
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.

Seekingalpha | 3 weeks ago

Viatris Inc. (US92556V1061) FAQ

What is the stock price today?

The current price is €9.22.

On which exchange is it traded?

Viatris Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is US92556V1061.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.48%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.53.

When is the next earnings date?

The next earnings report will release on Feb 26, 2026.

Has Viatris Inc. ever had a stock split?

Viatris Inc. had 10 splits and the recent split was on Oct 09, 2003.

Viatris Inc. Profile

- Industry
- Sector
Scott Andrew Smith CEO
XSTU Exchange
US92556V1061 ISIN
US Country
32,000 Employees
24 Nov 2025 Last Dividend
9 Oct 2003 Last Split
16 Nov 2020 IPO Date

Overview

Viatris Inc. is a global healthcare company that has marked its presence worldwide since its foundation in 1961, with its headquarters situated in Canonsburg, Pennsylvania. The company operates across various segments globally, including Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. Viatris is committed to providing access to medicines, sustainable operations, and community support, focusing on addressing the needs of patients in both noncommunicable and infectious disease domains. Its wide array of products stretches from prescription brand drugs to complex generics, biosimilars, and active pharmaceutical ingredients (APIs), catering to a broad spectrum of therapeutic areas and underpinning its mission to empower people worldwide to live healthier at every stage of life.

Products and Services

Viatris Inc.'s expansive portfolio encompasses a diverse range of healthcare solutions, from critical medicines to comprehensive support services, aimed at enhancing patient care and access:

  • Prescription Brand Drugs & Generics: Includes essential medications for various health conditions, ensuring patients have access to quality treatment options.
  • Complex Generic Drugs: Offers complex generics that are equivalent to brand-name drugs, providing more accessible and cost-effective treatment alternatives.
  • Biosimilars: The company produces biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology, offering high-quality alternatives to existing biologic drugs.
  • Active Pharmaceutical Ingredients (APIs): APIs for a vast range of therapeutic areas including antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, highlighting the breadth of Viatris’s capabilities in drug manufacturing.
  • Support Services: Beyond just providing medications, Viatris also facilitates diagnostic clinics, educational seminars, and digital tools to help individuals better manage their health, emphasizing the holistic approach to healthcare.

Medications are delivered in various forms, including oral solid doses, injectables, and complex dosage forms, ensuring versatility in administration ways to suit different patient needs. Distribution channels encompass pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order, e-commerce, and specialty pharmacies, ensuring broad accessibility. Products like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and the EpiPen auto-injector, among others, highlight the wide range and significance of Viatris’s offering in addressing global health issues. Through partnerships, like with Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc., Viatris Inc. continues to expand its portfolio, promising innovation and expanded access to essential medicines for patients worldwide.

Contact Information

Address: 1000 Mylan Boulevard
Phone: 724 514 1800